Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study. (2019). SKIN The Journal of Cutaneous Medicine, 3, S35. https://doi.org/10.25251/skin.3.supp.35